Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tricor/Statin Combo Could Have Edge Over Pfizer's Lipitor/Torcetrapib, Abbott Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Fenofibrate/statin combination also has advantage of known safety profile for both components, the company maintains.

You may also be interested in...



Abbott Pinning Tricor Growth On Improved Formulation, Combination Use

Company expects the lipid-lowering agent to eventually reach $1 bil. in revenue, almost double the U.S. sales level in 2003. Abbott points to "four strong formulation patents" on the fenofibrate tablet formulation which, it believes, will help keep generics at bay.

Pfizer's Lipitor-Torcetrapib Phase II Results Show HDL-LDL Double-Punch

Combination therapy trial reveals HDL-C increases of 61% for the drugs used together and 46% for torcetrapib alone. Pfizer is understood to be investing $800 mil. in the drug's development, including a $90 mil. manufacturing facility.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

UsernamePublicRestriction

Register

PS061122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel